Evaluation of fluorinated phospholipid analogs: A study on ADMET profiles, molecular docking and dynamics simulation

Saqib Ishaq1,2, Obaid Habib1, Abdul Aziz2

  • 1Guangdong Provincial Key Laboratory of System Biology and Synthetics Biology for Urogenital Tumors, School of Basic Medicine, Shenzhen University Medical School, Shenzhen University (SZU), Guangdong, China.

Heliyon
|February 3, 2025
PubMed

Insights

Edelfosine and Ilmofosine show potential as cancer therapies by interacting with heat shock protein (HSP70KDa1A). Edelfosine demonstrated superior binding stability and pharmacokinetic properties in computational analyses, suggesting it as a promising targeted cancer treatment.

Area of Science:

  • Oncology
  • Computational Chemistry
  • Biochemistry

Background:

  • Fluorinated phospholipid analogs, Edelfosine and Ilmofosine, are investigated for their antineoplastic properties.
  • Heat shock protein (HSP70KDa1A) is a key mediator in cancer pathophysiology and a potential therapeutic target.

Purpose of the Study:

  • To evaluate the absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles, receptor binding affinities, and molecular dynamics of Edelfosine and Ilmofosine.
  • To compare the computational profiles of Edelfosine and Ilmofosine for their potential as targeted cancer therapeutics.

Main Methods:

  • Computational approaches including molecular docking and 100 ns molecular dynamics simulations were employed.
  • Analysis of ADMET profiles, receptor binding affinities, and molecular dynamics was performed.
  • Functional annotation and phylogenetic investigation of HSP70KDa1A were conducted.

Main Results:

  • Edelfosine exhibited vigorous interactions with HSP70KDa1A, displaying greater binding stability and consistent hydrogen bonding compared to Ilmofosine.
  • Molecular dynamics simulations confirmed Edelfosine's enhanced pharmacokinetic properties, indicated by lower RMSD values and stable solvent-accessible surface area.
  • Phylogenetic analysis confirmed the evolutionary conservation and critical biological role of HSP70KDa1A.

Conclusions:

  • Edelfosine demonstrates superior binding stability and pharmacokinetic advantages over Ilmofosine.
  • Edelfosine is a promising candidate for targeted cancer therapy, warranting further experimental validation.
  • The study highlights the significance of HSP70KDa1A as a therapeutic target in cancer treatment.